#Sanofi and #GlaxoSmithKline have begun a new mid-stage study of a “refined” formulation of their adjuvanted recombinant protein-based #COVID19 candidate, with plans to advance to Phase III next quarter and reach the market by year’s end.
https://www.clinicalomics.com/topics/patient-care/therapeutics/vaccines/sanofis-gsks-refined-covid-19-vaccine-program-launches-phase-ii-trial/?utm_medium=newsletter&utm_source=Clinical+OMICs+Update&utm_content=01&utm_campaign=Clinical+OMICs+Update_20210223&oly_enc_id=6577H8138245E2Z